Published in Int J Hematol on December 12, 2012
Detection of MPLW515L/K mutations and determination of allele frequencies with a single-tube PCR assay. PLoS One (2014) 1.43
Normal and leukemic stem cell niches: insights and therapeutic opportunities. Cell Stem Cell (2015) 1.20
Targeted cancer exome sequencing reveals recurrent mutations in myeloproliferative neoplasms. Leukemia (2013) 1.06
Targeting phosphatidylinositol-3-kinase pathway for the treatment of Philadelphia-negative myeloproliferative neoplasms. Mol Cancer (2015) 0.82
l-Amino acid oxidase isolated from Calloselasma rhodostoma snake venom induces cytotoxicity and apoptosis in JAK2V617F-positive cell lines. Rev Bras Hematol Hemoter (2016) 0.81
Myeloproliferative neoplasms and inflammation: whether to target the malignant clone or the inflammatory process or both. Leukemia (2016) 0.81
Genomic landscape of megakaryopoiesis and platelet function defects. Blood (2016) 0.81
Individualizing kinase-targeted cancer therapy: the paradigm of chronic myeloid leukemia. Genome Biol (2014) 0.80
The molecular basis of myeloid malignancies. Proc Jpn Acad Ser B Phys Biol Sci (2014) 0.78
JAK2V617F mRNA metabolism in myeloproliferative neoplasm cell lines. Blood Cancer J (2014) 0.75
Epigenetic changes in myelofibrosis: Distinct methylation changes in the myeloid compartments and in cases with ASXL1 mutations. Sci Rep (2017) 0.75
Epigenetics in Myeloproliferative Neoplasms. J Cell Mol Med (2017) 0.75
CXCL12/CXCR4 pathway is activated by oncogenic JAK2 in a PI3K-dependent manner. Oncotarget (2016) 0.75
Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med (2013) 9.65
A mutation in VPS35, encoding a subunit of the retromer complex, causes late-onset Parkinson disease. Am J Hum Genet (2011) 4.52
JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes. Blood (2013) 3.78
A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms. Nat Genet (2009) 3.00
Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms. Blood (2014) 2.72
Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders. Blood (2007) 2.10
The JAK2-V617F mutation is frequently present at diagnosis in patients with essential thrombocythemia and polycythemia vera. Blood (2006) 1.89
A de novo splice donor mutation in the thrombopoietin gene causes hereditary thrombocythemia in a Polish family. Haematologica (2008) 1.63
Genome integrity of myeloproliferative neoplasms in chronic phase and during disease progression. Blood (2011) 1.63
An RNA-Seq strategy to detect the complete coding and non-coding transcriptome including full-length imprinted macro ncRNAs. PLoS One (2011) 1.53
p53 lesions in leukemic transformation. N Engl J Med (2011) 1.34
CALR exon 9 mutations are somatically acquired events in familial cases of essential thrombocythemia or primary myelofibrosis. Blood (2014) 1.30
Endemic polycythemia in Russia: mutation in the VHL gene. Blood Cells Mol Dis (2002) 1.28
Clonal heterogeneity in polycythemia vera patients with JAK2 exon12 and JAK2-V617F mutations. Blood (2008) 1.27
Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial. Blood (2013) 1.19
A reversible gene trap collection empowers haploid genetics in human cells. Nat Methods (2013) 1.17
Functional dissection of the TBK1 molecular network. PLoS One (2011) 1.16
Unique effects of KIT D816V in BaF3 cells: induction of cluster formation, histamine synthesis, and early mast cell differentiation antigens. J Immunol (2008) 1.15
Frequent deletions of JARID2 in leukemic transformation of chronic myeloid malignancies. Am J Hematol (2011) 1.09
The role of the JAK2 GGCC haplotype and the TET2 gene in familial myeloproliferative neoplasms. Haematologica (2010) 1.08
Germ-line JAK2 mutations in the kinase domain are responsible for hereditary thrombocytosis and are resistant to JAK2 and HSP90 inhibitors. Blood (2014) 0.98
Complex patterns of chromosome 11 aberrations in myeloid malignancies target CBL, MLL, DDB1 and LMO2. PLoS One (2013) 0.97
Nested high-resolution melting curve analysis a highly sensitive, reliable, and simple method for detection of JAK2 exon 12 mutations--clinical relevance in the monitoring of polycythemia. J Mol Diagn (2011) 0.93
Clinical significance of genetic aberrations in secondary acute myeloid leukemia. Am J Hematol (2012) 0.93
Identification of genomic aberrations associated with disease transformation by means of high-resolution SNP array analysis in patients with myeloproliferative neoplasm. Am J Hematol (2011) 0.93
Overexpression of primary microRNA 221/222 in acute myeloid leukemia. BMC Cancer (2013) 0.92
Common germline variation at the TERT locus contributes to familial clustering of myeloproliferative neoplasms. Am J Hematol (2014) 0.90
A novel germline JAK2 mutation in familial myeloproliferative neoplasms. Am J Hematol (2014) 0.89
Homologous recombination of wild-type JAK2, a novel early step in the development of myeloproliferative neoplasm. Blood (2011) 0.88
Unraveling the genetic underpinnings of myeloproliferative neoplasms and understanding their effect on disease course and response to therapy: proceedings from the 6th International Post-ASH Symposium. Am J Hematol (2012) 0.87
Role of germline genetic factors in MPN pathogenesis. Hematol Oncol Clin North Am (2012) 0.85
Identification of oncostatin M as a JAK2 V617F-dependent amplifier of cytokine production and bone marrow remodeling in myeloproliferative neoplasms. FASEB J (2011) 0.84
Molecular basis and clonal evolution of myeloproliferative neoplasms. Haematologica (2010) 0.84
Acquired resistance to interferon alpha therapy associated with homozygous MPL-W515L mutation and chromosome 20q deletion in primary myelofibrosis. Eur J Haematol (2008) 0.84
A downstream CpG island controls transcript initiation and elongation and the methylation state of the imprinted Airn macro ncRNA promoter. PLoS Genet (2012) 0.83
β Thalassemia major due to acquired uniparental disomy in a previously healthy adolescent. Haematologica (2012) 0.80
Restoration of response to ruxolitinib upon brief withdrawal in two patients with myelofibrosis. Am J Hematol (2014) 0.78
Efficacy of ruxolitinib in chronic eosinophilic leukemia associated with a PCM1-JAK2 fusion gene. J Clin Oncol (2013) 0.78
JAK inhibitor in CALR-mutant myelofibrosis. N Engl J Med (2014) 0.77
Molecular basis and clonal evolution of myeloproliferative neoplasms. Clin Chem Lab Med (2013) 0.76
Genetic basis of MPN: Beyond JAK2-V617F. Curr Hematol Malig Rep (2013) 0.76
Molecular responses and chromosomal aberrations in patients with polycythemia vera treated with peg-proline-interferon alpha-2b. Am J Hematol (2015) 0.76
Decanucleotide insertion polymorphism of F7 significantly influences the risk of thrombosis in patients with essential thrombocythemia. Eur J Haematol (2014) 0.76
Novel insights into the biology and treatment of chronic myeloproliferative neoplasms. Leuk Lymphoma (2014) 0.76
Paul Ehrlich (1854-1915) and His Contributions to the Foundation and Birth of Translational Medicine. J Innate Immun (2016) 0.75
8p11 myeloproliferative syndrome: diagnostic challenges and pitfalls. J BUON (2016) 0.75
Molecular pathogenesis of Philadelphia chromosome negative chronic myeloproliferative neoplasms. Curr Cancer Drug Targets (2011) 0.75